Dr. Rachel Rubin outlines how simple, low-dose vaginal estrogen—backed by the 2025 AUA GSM guideline—can prevent recurrent UTIs, relieve symptoms, and save lives. A must-watch for providers treating menopausal patients.
This was a very important meeting with top experts that are trying to change guidelines. This FDA panel recently recommended removing the warning (“black box”) labels on menopausal HRT, citing potential benefits like reduced heart attack and bone fracture risk—and arguing the warning discourages appropriate use.
Hopefully, we will see progress in this field after the confusing and sometimes misleading conclusions of the WHI (“Women’s Health Initiative”), a large National Institutes of Health trial...
Dr. Rachel Rubin and Dr. Kelly Caspersen discuss with FDA Commissioner Dr. Marty Makary the significant impact of hormone replacement therapy (HRT) on women's health, particularly in the context of recent FDA changes to black box warnings. They explore the misconceptions surrounding HRT, the importance of education for both clinicians and patients, and the long-term health benefits of hormone therapy. The discussion emphasizes the need for accurate labeling, comprehensive care, and empowering women to make informed choices about their health...
* Key discussions include the safety and efficacy of low-dose local vaginal estrogen, the importance of a patient-centered, shared decision-making approach, and clear consensus on when to use various therapies.
The new interdisciplinary guidelines for the Genitourinary Syndrome of Menopause (GSM) represent a critical, evidence-based advancement in women's health. Host Rachel S. Rubin, MD, is joined by co-chairs Melissa Kaufman, MD, PhD, and Una Lee, MD, to discuss the impact, scope, and key recommendations of this landmark...
ExcelMale Newsletter Signup
Stay Informed with Our Newsletter
Get the latest men's health insights, expert advice, and community updates delivered to your inbox.